Palavras-chave
Obesidade
Saúde vascular
Semaglutida
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Avaliar os efeitos da semaglutida sobre os desfechos cardiovasculares em adultos com obesidade, independentemente de sua ação sobre a perda de peso. Métodos: Trata-se de uma revisão integrativa da literatura realizada através das bases PubMed Central (PMC), Biblioteca Virtual em Saúde (BVS) e Periódico CAPES, usando os descritores em combinação com o termo booleano “AND”: Semaglutid, Cardiovascular Diseases e Obesity. Foram encontrados 986 totais de artigos, filtrados conforme critérios de inclusão (idioma inglês; período de 2021 a 2026) e exclusão (artigos duplicados, resumos, fora do escopo). Dessa busca, foram selecionados 20 artigos para compor a pesquisa. Resultados: A semaglutida demonstrou benefícios consistentes em pacientes com obesidade, independente do controle glicêmico e da diabetes, incluindo perda de peso, melhora das limitações físicas, capacidade de exercício, redução de eventos cardiovasculares e renais, ação anti-inflamatória e cardiometabólica. O tratamento com semaglutida ainda apresentou perfil de segurança favorável quando comparado ao placebo. Esses benefícios, contudo, estão associados a um aumento do risco de efeitos gastrointestinais adversos e de doenças da vesícula biliar. Considerações finais: A semaglutida demonstra benefícios independentes do controle glicêmico, incluindo redução da inflamação, melhora de biomarcadores cardíacos e remodelação cardíaca favorável, sustentando seu potencial como terapia cardiometabólica.
Referências
AN P, et al. Micronutrient supplementation to reduce cardiovascular risk. Journal of the American College of Cardiology, 2022; 80(24): 2269–2285.
BORLAUG B, et al. Semaglutide and exercise function in obesity-related HFpEF: Insights from the STEP-HFpEF Program. JACC. Heart Failure, 2025; 13(11): 102660.
BUTLER J, et al. Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction. Journal of the American College of Cardiology, 2023; 82(22): 2087–2096.
BUTLER J, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet, 2024; 403(10437): 1635–1648.
COLHOUN H, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature Medicine, 2024; 30(7): 2058–2066.
DEANFIELD J, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet, 2024; 404(10454): 773–786.
DEANFIELD J, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet, 2025; 406(10516): 2257–2268.
GALLI M, et al. Cardiovascular effects and tolerability of GLP-1 receptor agonists: A Systematic Review and meta-Analysis of 99,599 patients. Journal of the American College of Cardiology, 2025; 86(20): 1805–1819.
GARCÍA-VEGA D, et al. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network. Cardiovascular Diabetology, 2024; 23(1): 1.
HU E, et al. A review and meta-analysis of the safety and efficacy of using glucagon-like peptide-1 receptor agonists. Medicina (Kaunas, Lithuania), 2024; 60(3): 357.
HWANG J, et al. Lifetime health effects and cost-effectiveness of tirzepatide and semaglutide in US adults. JAMA Health Forum, 2025; 6(3): e245586.
KOSIBOROD M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. The New England Journal of Medicine, 2023; 389(12): 1069–1084.
KOSIBOROD M, et al. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: A prespecified analysis of the STEP-HFpEF trial. Circulation, 2024; 149(3): 204–216.
LINCOFF A, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 2023; 389(24): 2221–2232.
LINGVAY I, et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring, Md.), 2022; 31(1): 111–122.
LINGVAY I, et al. Semaglutide and Cardiovascular Outcomes by baseline HbA1c and change in HbA1c in People With Overweight or obesity but without diabetes in SELECT. Diabetes Care, 2024; 47(8): 1360–1369.
LIU L, et al. Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis. EClinicalMedicine, 2025; 79(103020): 103020.
LÜBKER C, et al. The composite number needed to treat for semaglutide in populations with overweight or obesity and established cardiovascular disease without diabetes. Advances in Therapy, 2025; 42(5): 2513–2525.
MARETTY L, et al. Proteomic changes upon treatment with semaglutide in individuals with obesity. Nature Medicine, 2025; 31(1): 267–277.
NANNA M, et al. Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial. Diabetes, Obesity & Metabolism, 2025; 27(6): 3442–3452.
SCHOU M, et al. Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction: The STEP-HFpEF program. Journal of the American College of Cardiology, 2024; 84(3): 247–257.
SHAH S, et al. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials. European Heart Journal, 2024; 45(35): 3254–3269.
SOLOMON S, et al. Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure. Journal of the American College of Cardiology, 2024; 84 (17): 1587–1602.
TANG H, et al. Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study. Diabetes, Obesity & Metabolism, 2025; 27(11): 6527–6536.
VERMA S, et al. Atrial fibrillation and semaglutide effects in obesity-related heart failure with preserved ejection fraction. Journal of the American College of Cardiology, 2024; 84(17): 1603–1614.
WU R, et al. Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis. European Journal of Medical Research, 2025; 30(1): 835.